default author photo

Alexandra Apollon

Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO)

SCHOLARLY PAPERS

2

DOWNLOADS

201

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Ritonavir-Boosted Protease Inhibitor-Based Antiretroviral Therapy in Persons with HIV and Viral Suppression on Second-Line Therapy: An Open-Label Randomized Non-Inferiority Trial

Number of pages: 27 Posted: 02 Jan 2025
Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Harvard University - Department of Global Health and Social Medicine, Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Analysis Group, Inc., Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Analysis Group, Inc., Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), National Institute of Respiratory Diseases ”Ismael Cosío Villegas” - Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Analysis Group, Inc., Gilead Sciences, Inc., Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Cornell University, Analysis Group, Inc., Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Gilead Sciences, Inc., Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Harvard University - Division of Infectious Disease and Harvard University - Harvard Medical School
Downloads 146 (505,974)

Abstract:

Loading...

HIV, INSTI, bictegravir, protease inhibitor, tenofovir alafenamide, tenofovir disoproxil fumarate

2.

Final 18-month Outcomes of a Trial of Four-Month Rifapentine Regimens With or Without Moxifloxacin for Tuberculosis

Number of pages: 18 Posted: 20 Feb 2026
University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis, Centers for Disease Control and Prevention (U.S., Medical University of South Carolina, Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (CDC), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of Tuberculosis Elimination, Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Vanderbilt University - Medical Center, University of California, San Francisco (UCSF) - Department of Bioengineering and Therapeutic Sciences, Case Western Reserve University, Bio Analytical Research Corporation South Africa (BARC SA), National Lung Hospital, Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Johns Hopkins University, University of Nebraska Medical Center and University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis
Downloads 55 (1,010,164)

Abstract:

Loading...

tuberculosis, non-inferiority, rifapentine, moxifloxacin